Japan begins trials of first AI drug

As a rule, it takes three to five years to develop a new medicine, after which the testing phase begins with the participation of volunteers. British startup AI Exscientia and Japanese pharmaceutical company Sumitomo Dainippon Pharma intend to shorten these terms to 1 year.

This is the promising drug DSP-1181 for the treatment of obsessive-compulsive disorder (OCD), a severe mental illness that affects millions of people around the world.

Exscientia, based in Oxford, UK, has a unique machine learning platform called Centaur Chemist. With its help, using AI technology, the company is going to significantly speed up work on the creation of a new drug.

The advantage of this approach is that the AI ​​can analyze millions of molecular combinations and try to determine which ones will be most effective in treating OCD. As a result, faster drug development times will save billions of dollars.